Annual CFO
-$14.09 M
+$3.05 M+17.80%
December 31, 2023
Summary
- As of February 8, 2025, ENVB annual cash flow from operations is -$14.09 million, with the most recent change of +$3.05 million (+17.80%) on December 31, 2023.
- During the last 3 years, ENVB annual CFO has fallen by -$10.21 million (-262.44%).
- ENVB annual CFO is now -4198.40% below its all-time high of $343.90 thousand, reached on December 31, 2004.
Performance
ENVB Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$927.10 K
+$1.96 M+67.91%
September 30, 2024
Summary
- As of February 8, 2025, ENVB quarterly cash flow from operations is -$927.10 thousand, with the most recent change of +$1.96 million (+67.91%) on September 30, 2024.
- Over the past year, ENVB quarterly CFO has increased by +$1.96 million (+67.91%).
- ENVB quarterly CFO is now -188.46% below its all-time high of $1.05 million, reached on June 30, 2020.
Performance
ENVB Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$8.17 M
+$1.81 M+18.17%
September 30, 2024
Summary
- As of February 8, 2025, ENVB TTM cash flow from operations is -$8.17 million, with the most recent change of +$1.81 million (+18.17%) on September 30, 2024.
- Over the past year, ENVB TTM CFO has increased by +$1.81 million (+18.17%).
- ENVB TTM CFO is now -2110.74% below its all-time high of $406.10 thousand, reached on June 30, 2007.
Performance
ENVB TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ENVB Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +17.8% | +67.9% | +18.2% |
| 3 y3 years | -262.4% | +73.2% | +52.4% |
| 5 y5 years | -449.4% | -100.0% | -267.1% |
ENVB Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -23.0% | +17.8% | at high | +82.0% | at high | +54.0% |
| 5 y | 5-year | -474.6% | +17.8% | -188.5% | +82.0% | -267.1% | +54.0% |
| alltime | all time | -4198.4% | +17.8% | -188.5% | +82.0% | -2110.7% | +54.0% |
Enveric Biosciences Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$927.10 K(-67.9%) | -$8.17 M(-18.2%) |
| Jun 2024 | - | -$2.89 M(+11.2%) | -$9.98 M(-13.6%) |
| Mar 2024 | - | -$2.60 M(+48.4%) | -$11.56 M(-18.0%) |
| Dec 2023 | -$14.09 M(-17.8%) | -$1.75 M(-36.1%) | -$14.09 M(-10.8%) |
| Sep 2023 | - | -$2.74 M(-38.6%) | -$15.81 M(-10.3%) |
| Jun 2023 | - | -$4.47 M(-13.1%) | -$17.62 M(-0.7%) |
| Mar 2023 | - | -$5.14 M(+48.4%) | -$17.73 M(+3.4%) |
| Dec 2022 | -$17.15 M(+49.7%) | -$3.46 M(-23.9%) | -$17.15 M(-3.4%) |
| Sep 2022 | - | -$4.55 M(-0.8%) | -$17.75 M(+15.2%) |
| Jun 2022 | - | -$4.59 M(+0.8%) | -$15.41 M(+20.0%) |
| Mar 2022 | - | -$4.55 M(+11.8%) | -$12.84 M(+12.1%) |
| Dec 2021 | -$11.46 M(+194.6%) | -$4.07 M(+84.4%) | -$11.46 M(+18.9%) |
| Sep 2021 | - | -$2.21 M(+9.1%) | -$9.64 M(+23.2%) |
| Jun 2021 | - | -$2.02 M(-36.1%) | -$7.83 M(+64.5%) |
| Mar 2021 | - | -$3.16 M(+40.5%) | -$4.76 M(+22.4%) |
| Dec 2020 | -$3.89 M(+58.5%) | -$2.25 M(+471.5%) | -$3.89 M(+48.6%) |
| Sep 2020 | - | -$393.70 K(-137.6%) | -$2.62 M(+17.7%) |
| Jun 2020 | - | $1.05 M(-145.7%) | -$2.22 M(-40.9%) |
| Mar 2020 | - | -$2.29 M(+134.2%) | -$3.76 M(+53.4%) |
| Dec 2019 | -$2.45 M(-4.4%) | -$979.00 K(<-9900.0%) | -$2.45 M(-1.0%) |
| Sep 2019 | - | $0.00(-100.0%) | -$2.48 M(-34.1%) |
| Jun 2019 | - | -$490.00 K(-50.2%) | -$3.76 M(+21.7%) |
| Mar 2019 | - | -$984.10 K(-1.9%) | -$3.09 M(+20.4%) |
| Dec 2018 | -$2.57 M(-6.4%) | -$1.00 M(-21.8%) | -$2.57 M(+2.5%) |
| Sep 2018 | - | -$1.28 M(-812.1%) | -$2.50 M(+89.8%) |
| Jun 2018 | - | $180.20 K(-139.2%) | -$1.32 M(-44.2%) |
| Mar 2018 | - | -$459.60 K(-51.2%) | -$2.36 M(-13.8%) |
| Dec 2017 | -$2.74 M(+1.4%) | -$941.20 K(+854.6%) | -$2.74 M(+82.0%) |
| Sep 2017 | - | -$98.60 K(-88.6%) | -$1.51 M(-64.5%) |
| Jun 2017 | - | -$863.10 K(+3.0%) | -$4.24 M(+14.7%) |
| Mar 2017 | - | -$837.90 K(-385.4%) | -$3.69 M(+36.6%) |
| Dec 2016 | -$2.70 M(-30.7%) | $293.60 K(-110.4%) | -$2.70 M(-9.8%) |
| Sep 2016 | - | -$2.83 M(+786.8%) | -$3.00 M(-12.2%) |
| Jun 2016 | - | -$319.30 K(-308.6%) | -$3.41 M(-18.1%) |
| Mar 2016 | - | $153.10 K(-104.7%) | -$4.17 M(-3.7%) |
| Dec 2015 | -$3.90 M(+8933.8%) | - | - |
| Sep 2015 | - | -$3.25 M(+203.1%) | -$4.33 M(+302.1%) |
| Jun 2015 | - | -$1.07 M(>+9900.0%) | -$1.08 M(+6380.7%) |
| Mar 2015 | - | -$1200.00(-70.0%) | -$16.60 K(-61.6%) |
| Dec 2014 | -$43.20 K(+100.0%) | -$4000.00(-407.7%) | -$43.20 K(+9.1%) |
| Sep 2014 | - | $1300.00(-110.2%) | -$39.60 K(-14.1%) |
| Jun 2014 | - | -$12.70 K(-54.3%) | -$46.10 K(+24.3%) |
| Mar 2014 | - | -$27.80 K(+6850.0%) | -$37.10 K(+72.6%) |
| Dec 2013 | -$21.60 K(-13.3%) | -$400.00(-92.3%) | -$21.50 K(-13.7%) |
| Sep 2013 | - | -$5200.00(+40.5%) | -$24.90 K(+0.4%) |
| Jun 2013 | - | -$3700.00(-69.7%) | -$24.80 K(-0.8%) |
| Mar 2013 | - | -$12.20 K(+221.1%) | -$25.00 K(+0.4%) |
| Dec 2012 | -$24.90 K(-17.8%) | -$3800.00(-25.5%) | -$24.90 K(-3.9%) |
| Sep 2012 | - | -$5100.00(+30.8%) | -$25.90 K(+5.7%) |
| Jun 2012 | - | -$3900.00(-67.8%) | -$24.50 K(-3.9%) |
| Mar 2012 | - | -$12.10 K(+152.1%) | -$25.50 K(-16.1%) |
| Dec 2011 | -$30.30 K(-25.6%) | -$4800.00(+29.7%) | -$30.40 K(+6.3%) |
| Sep 2011 | - | -$3700.00(-24.5%) | -$28.60 K(-55.2%) |
| Jun 2011 | - | -$4900.00(-71.2%) | -$63.80 K(+93.9%) |
| Mar 2011 | - | -$17.00 K(+466.7%) | -$32.90 K(-19.0%) |
| Dec 2010 | -$40.70 K | -$3000.00(-92.3%) | -$40.60 K(-11.0%) |
| Sep 2010 | - | -$38.90 K(-249.6%) | -$45.60 K(+342.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2010 | - | $26.00 K(-205.3%) | -$10.30 K(-82.5%) |
| Mar 2010 | - | -$24.70 K(+208.8%) | -$58.70 K(-9.7%) |
| Dec 2009 | -$65.00 K(-56.7%) | -$8000.00(+122.2%) | -$65.00 K(-25.5%) |
| Sep 2009 | - | -$3600.00(-83.9%) | -$87.20 K(-5.0%) |
| Jun 2009 | - | -$22.40 K(-27.7%) | -$91.80 K(-32.5%) |
| Mar 2009 | - | -$31.00 K(+2.6%) | -$135.90 K(-9.5%) |
| Dec 2008 | -$150.20 K(-145.5%) | -$30.20 K(+268.3%) | -$150.10 K(+9.5%) |
| Sep 2008 | - | -$8200.00(-87.7%) | -$137.10 K(-40.9%) |
| Jun 2008 | - | -$66.50 K(+47.1%) | -$232.00 K(+4.4%) |
| Mar 2008 | - | -$45.20 K(+162.8%) | -$222.30 K(-167.4%) |
| Dec 2007 | $329.90 K(-207.8%) | -$17.20 K(-83.3%) | $329.90 K(+3.9%) |
| Sep 2007 | - | -$103.10 K(+81.5%) | $317.60 K(-21.8%) |
| Jun 2007 | - | -$56.80 K(-111.2%) | $406.10 K(+4.4%) |
| Mar 2007 | - | $507.00 K(-1818.6%) | $389.00 K(-227.2%) |
| Dec 2006 | -$305.90 K(+19.2%) | -$29.50 K(+102.1%) | -$305.90 K(-17.6%) |
| Sep 2006 | - | -$14.60 K(-80.2%) | -$371.40 K(-2.6%) |
| Jun 2006 | - | -$73.90 K(-60.7%) | -$381.20 K(-20.1%) |
| Mar 2006 | - | -$187.90 K(+97.8%) | -$477.30 K(+86.1%) |
| Dec 2005 | -$256.60 K(-174.6%) | -$95.00 K(+289.3%) | -$256.50 K(+50.2%) |
| Sep 2005 | - | -$24.40 K(-85.6%) | -$170.80 K(-145.0%) |
| Jun 2005 | - | -$170.00 K(-616.7%) | $379.40 K(+27.8%) |
| Mar 2005 | - | $32.90 K(-453.8%) | $296.80 K(-13.7%) |
| Dec 2004 | $343.90 K(-235.4%) | -$9300.00(-101.8%) | $343.90 K(+16.1%) |
| Sep 2004 | - | $525.80 K(-308.2%) | $296.30 K(-197.6%) |
| Jun 2004 | - | -$252.60 K(-415.8%) | -$303.60 K(+44.2%) |
| Mar 2004 | - | $80.00 K(-240.6%) | -$210.50 K(-17.1%) |
| Dec 2003 | -$254.00 K(-398.5%) | -$56.90 K(-23.2%) | -$253.90 K(+1.5%) |
| Sep 2003 | - | -$74.10 K(-53.5%) | -$250.10 K(+20.2%) |
| Jun 2003 | - | -$159.50 K(-535.8%) | -$208.00 K(-608.6%) |
| Mar 2003 | - | $36.60 K(-168.9%) | $40.90 K(-51.9%) |
| Dec 2002 | $85.10 K(-125.1%) | -$53.10 K(+65.9%) | $85.10 K(-64.7%) |
| Sep 2002 | - | -$32.00 K(-135.8%) | $241.10 K(+136.8%) |
| Jun 2002 | - | $89.40 K(+10.6%) | $101.80 K(-144.1%) |
| Mar 2002 | - | $80.80 K(-21.5%) | -$231.00 K(-32.0%) |
| Dec 2001 | -$339.70 K(-333.0%) | $102.90 K(-160.1%) | -$339.70 K(-18.3%) |
| Sep 2001 | - | -$171.30 K(-29.6%) | -$415.80 K(+96.1%) |
| Jun 2001 | - | -$243.40 K(+772.4%) | -$212.00 K(+42.1%) |
| Mar 2001 | - | -$27.90 K(-204.1%) | -$149.20 K(-202.3%) |
| Dec 2000 | $145.80 K(-121.9%) | $26.80 K(-17.5%) | $145.80 K(+22.5%) |
| Sep 2000 | - | $32.50 K(-118.0%) | $119.00 K(+37.6%) |
| Jun 2000 | - | -$180.60 K(-167.6%) | $86.50 K(-67.6%) |
| Mar 2000 | - | $267.10 K(+158.8%) | $267.10 K(-108.9%) |
| Dec 1999 | -$665.40 K(-77.8%) | - | - |
| Dec 1998 | -$3.00 M(-19.0%) | $103.20 K(-125.8%) | -$3.00 M(-30.3%) |
| Sep 1998 | - | -$400.00 K(-81.0%) | -$4.30 M(-2.3%) |
| Jun 1998 | - | -$2.10 M(+250.0%) | -$4.40 M(+33.4%) |
| Mar 1998 | - | -$600.00 K(-49.9%) | -$3.30 M(-10.8%) |
| Dec 1997 | -$3.70 M(-21.7%) | -$1.20 M(+139.5%) | -$3.70 M(-5.8%) |
| Sep 1997 | - | -$500.00 K(-50.0%) | -$3.92 M(-15.1%) |
| Jun 1997 | - | -$1.00 M(0.0%) | -$4.62 M(-6.1%) |
| Mar 1997 | - | -$1.00 M(-29.8%) | -$4.92 M(+4.2%) |
| Dec 1996 | -$4.72 M(+31.2%) | -$1.42 M(+18.7%) | -$4.72 M(+43.2%) |
| Sep 1996 | - | -$1.20 M(-7.7%) | -$3.30 M(+57.1%) |
| Jun 1996 | - | -$1.30 M(+62.5%) | -$2.10 M(+162.5%) |
| Mar 1996 | - | -$800.00 K | -$800.00 K |
| Dec 1995 | -$3.60 M(+350.0%) | - | - |
| Dec 1994 | -$800.00 K(-60.0%) | - | - |
| Aug 1994 | -$2.00 M | - | - |
FAQ
- What is Enveric Biosciences annual cash flow from operations?
- What is the all time high annual CFO for Enveric Biosciences?
- What is Enveric Biosciences annual CFO year-on-year change?
- What is Enveric Biosciences quarterly cash flow from operations?
- What is the all time high quarterly CFO for Enveric Biosciences?
- What is Enveric Biosciences quarterly CFO year-on-year change?
- What is Enveric Biosciences TTM cash flow from operations?
- What is the all time high TTM CFO for Enveric Biosciences?
- What is Enveric Biosciences TTM CFO year-on-year change?
What is Enveric Biosciences annual cash flow from operations?
The current annual CFO of ENVB is -$14.09 M
What is the all time high annual CFO for Enveric Biosciences?
Enveric Biosciences all-time high annual cash flow from operations is $343.90 K
What is Enveric Biosciences annual CFO year-on-year change?
Over the past year, ENVB annual cash flow from operations has changed by +$3.05 M (+17.80%)
What is Enveric Biosciences quarterly cash flow from operations?
The current quarterly CFO of ENVB is -$927.10 K
What is the all time high quarterly CFO for Enveric Biosciences?
Enveric Biosciences all-time high quarterly cash flow from operations is $1.05 M
What is Enveric Biosciences quarterly CFO year-on-year change?
Over the past year, ENVB quarterly cash flow from operations has changed by +$1.96 M (+67.91%)
What is Enveric Biosciences TTM cash flow from operations?
The current TTM CFO of ENVB is -$8.17 M
What is the all time high TTM CFO for Enveric Biosciences?
Enveric Biosciences all-time high TTM cash flow from operations is $406.10 K
What is Enveric Biosciences TTM CFO year-on-year change?
Over the past year, ENVB TTM cash flow from operations has changed by +$1.81 M (+18.17%)